Concepedia

Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System

Emanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, Nicolò Bendinelli, Emanuele Forcesi, Marco Tuccori, Ugo Moretti, Elisabetta Poluzzi, Fabrizio De Ponti

Targeted Oncology · 2019 · 97 citations · 38 references

DOIFull text

Open access

Concepts

References

38

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.7K citations · Full text

, , +17

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Douglas B. Johnson, Justin M. Balko, Margaret Compton et al. · New England Journal of Medicine · 2016 · 2.3K citations · Full text

, , +17

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Joe‐Elie Salem, Ali Manouchehri, Melissa Moey et al. · The Lancet Oncology · 2018 · 1.2K citations

, , +16

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari et al. · Clinical Cancer Research · 2016 · 1.2K citations

, , +17

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba et al. · JAMA Oncology · 2017 · 1K citations

, , +17